 Carlos Roncal
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uric Acid | 14 | 2019 | 354 | 1.060 |
Why?
| | Fructose | 13 | 2018 | 206 | 1.050 |
Why?
| | Kidney Diseases | 9 | 2019 | 427 | 0.860 |
Why?
| | Hyperuricemia | 8 | 2019 | 134 | 0.630 |
Why?
| | Metabolic Syndrome | 7 | 2018 | 393 | 0.610 |
Why?
| | Allopurinol | 4 | 2019 | 86 | 0.500 |
Why?
| | Diabetic Nephropathies | 6 | 2019 | 289 | 0.440 |
Why?
| | Kidney | 11 | 2019 | 1247 | 0.430 |
Why?
| | Nephritis, Interstitial | 2 | 2007 | 15 | 0.390 |
Why?
| | Captopril | 1 | 2009 | 13 | 0.370 |
Why?
| | Antimetabolites | 1 | 2009 | 28 | 0.370 |
Why?
| | Uromodulin | 2 | 2019 | 27 | 0.350 |
Why?
| | Rats, Sprague-Dawley | 15 | 2019 | 2547 | 0.340 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 227 | 0.320 |
Why?
| | Arteriolosclerosis | 1 | 2007 | 2 | 0.320 |
Why?
| | Rats | 18 | 2019 | 5516 | 0.320 |
Why?
| | Lead | 1 | 2007 | 62 | 0.300 |
Why?
| | Cisplatin | 1 | 2007 | 269 | 0.270 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2019 | 3347 | 0.270 |
Why?
| | Vascular Stiffness | 2 | 2019 | 412 | 0.250 |
Why?
| | Glomerular Filtration Rate | 5 | 2019 | 641 | 0.240 |
Why?
| | Hypokalemia | 3 | 2008 | 35 | 0.240 |
Why?
| | Glucose | 5 | 2018 | 962 | 0.240 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 651 | 0.230 |
Why?
| | Albuminuria | 3 | 2019 | 184 | 0.230 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 916 | 0.210 |
Why?
| | Dietary Sucrose | 3 | 2010 | 55 | 0.200 |
Why?
| | Chemokine CCL2 | 4 | 2009 | 126 | 0.190 |
Why?
| | Creatinine | 6 | 2018 | 479 | 0.190 |
Why?
| | Glycocalyx | 1 | 2019 | 19 | 0.180 |
Why?
| | Kidney Tubules | 4 | 2008 | 123 | 0.180 |
Why?
| | Glycopeptides | 1 | 2019 | 63 | 0.180 |
Why?
| | Animals | 26 | 2019 | 34126 | 0.170 |
Why?
| | Kidney Calculi | 1 | 2018 | 32 | 0.170 |
Why?
| | Heat-Shock Response | 1 | 2018 | 58 | 0.170 |
Why?
| | Sweetening Agents | 2 | 2009 | 54 | 0.170 |
Why?
| | Dehydration | 2 | 2016 | 63 | 0.170 |
Why?
| | Hydrochlorothiazide | 2 | 2007 | 11 | 0.160 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 50 | 0.160 |
Why?
| | Sugars | 1 | 2018 | 29 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2009 | 157 | 0.160 |
Why?
| | Diuretics | 2 | 2007 | 80 | 0.150 |
Why?
| | Proteinuria | 5 | 2008 | 92 | 0.150 |
Why?
| | Hypertension, Renal | 2 | 2007 | 28 | 0.150 |
Why?
| | Oxidative Stress | 4 | 2019 | 1194 | 0.150 |
Why?
| | Survival | 1 | 2016 | 40 | 0.150 |
Why?
| | Water Supply | 1 | 2016 | 75 | 0.140 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2016 | 0.140 |
Why?
| | Male | 23 | 2019 | 60425 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2016 | 106 | 0.130 |
Why?
| | Heat Stress Disorders | 1 | 2015 | 60 | 0.130 |
Why?
| | Farmers | 1 | 2015 | 66 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 271 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2008 | 525 | 0.130 |
Why?
| | Climate Change | 1 | 2016 | 150 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2018 | 465 | 0.120 |
Why?
| | Macrophages | 4 | 2010 | 1328 | 0.120 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1732 | 0.110 |
Why?
| | Inflammation | 3 | 2008 | 2522 | 0.110 |
Why?
| | Kidney Tubules, Proximal | 2 | 2010 | 84 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 1007 | 0.110 |
Why?
| | Blood Pressure | 6 | 2009 | 1717 | 0.110 |
Why?
| | Liver | 2 | 2018 | 1832 | 0.110 |
Why?
| | Body Weight | 4 | 2009 | 1001 | 0.110 |
Why?
| | Drug Synergism | 2 | 2009 | 339 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2009 | 177 | 0.100 |
Why?
| | Hypertension | 4 | 2008 | 1241 | 0.100 |
Why?
| | Urate Oxidase | 2 | 2008 | 31 | 0.100 |
Why?
| | Disease Models, Animal | 6 | 2009 | 3798 | 0.090 |
Why?
| | Capillaries | 2 | 2007 | 104 | 0.090 |
Why?
| | Insulin Resistance | 5 | 2009 | 1174 | 0.090 |
Why?
| | Animal Feed | 1 | 2009 | 58 | 0.090 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 82 | 0.090 |
Why?
| | Angiostatins | 1 | 2008 | 4 | 0.090 |
Why?
| | Cells, Cultured | 6 | 2019 | 4145 | 0.080 |
Why?
| | Weight Gain | 2 | 2008 | 520 | 0.080 |
Why?
| | Kidney Glomerulus | 1 | 2008 | 113 | 0.080 |
Why?
| | Biomarkers | 4 | 2019 | 3650 | 0.080 |
Why?
| | Chronic Disease | 3 | 2008 | 1655 | 0.080 |
Why?
| | Leptin | 1 | 2008 | 232 | 0.080 |
Why?
| | Fatty Liver | 1 | 2009 | 250 | 0.070 |
Why?
| | Renal Circulation | 1 | 2006 | 62 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 1003 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2008 | 145 | 0.070 |
Why?
| | Dietary Fats | 1 | 2008 | 339 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 2046 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 292 | 0.070 |
Why?
| | Inflammation Mediators | 2 | 2008 | 509 | 0.070 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 560 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 842 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2009 | 2167 | 0.070 |
Why?
| | Nitric Oxide | 5 | 2008 | 868 | 0.070 |
Why?
| | Young Adult | 5 | 2019 | 11215 | 0.070 |
Why?
| | Gout Suppressants | 2 | 2019 | 33 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 137 | 0.060 |
Why?
| | Chemokines | 1 | 2005 | 230 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 853 | 0.060 |
Why?
| | Fructokinases | 2 | 2018 | 63 | 0.060 |
Why?
| | Risk Factors | 4 | 2019 | 9403 | 0.060 |
Why?
| | Interleukin-10 | 1 | 2005 | 304 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2009 | 869 | 0.060 |
Why?
| | Organ Size | 3 | 2010 | 482 | 0.060 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 513 | 0.060 |
Why?
| | Humans | 18 | 2019 | 121723 | 0.060 |
Why?
| | Rats, Wistar | 2 | 2018 | 399 | 0.060 |
Why?
| | Endothelial Cells | 1 | 2008 | 709 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2007 | 2746 | 0.050 |
Why?
| | Adolescent | 5 | 2019 | 19118 | 0.050 |
Why?
| | Aorta | 2 | 2019 | 374 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2361 | 0.050 |
Why?
| | Blotting, Western | 3 | 2008 | 1226 | 0.050 |
Why?
| | Fibrosis | 3 | 2008 | 482 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3314 | 0.050 |
Why?
| | Blood Urea Nitrogen | 2 | 2009 | 59 | 0.040 |
Why?
| | Calcium Oxalate | 1 | 2018 | 6 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 150 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 131 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 32 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 34 | 0.040 |
Why?
| | Pulse Wave Analysis | 1 | 2019 | 214 | 0.040 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 10 | 0.040 |
Why?
| | Carbonated Beverages | 1 | 2018 | 19 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 308 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 190 | 0.040 |
Why?
| | Beverages | 1 | 2018 | 70 | 0.040 |
Why?
| | Lipogenesis | 1 | 2018 | 71 | 0.040 |
Why?
| | Potassium | 2 | 2008 | 151 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 496 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 580 | 0.040 |
Why?
| | Female | 6 | 2019 | 63833 | 0.040 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 272 | 0.040 |
Why?
| | Sodium | 2 | 2007 | 202 | 0.040 |
Why?
| | Administration, Oral | 1 | 2018 | 793 | 0.040 |
Why?
| | Cystatin C | 1 | 2015 | 67 | 0.040 |
Why?
| | El Salvador | 1 | 2015 | 7 | 0.030 |
Why?
| | Adult | 4 | 2019 | 32638 | 0.030 |
Why?
| | Metformin | 1 | 2019 | 301 | 0.030 |
Why?
| | Eating | 1 | 2018 | 395 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 946 | 0.030 |
Why?
| | Models, Biological | 2 | 2015 | 1771 | 0.030 |
Why?
| | Child | 3 | 2019 | 19271 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 479 | 0.030 |
Why?
| | Saccharum | 1 | 2015 | 85 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 530 | 0.030 |
Why?
| | Insulin | 3 | 2008 | 2155 | 0.030 |
Why?
| | Mice, Inbred C57BL | 3 | 2009 | 5052 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1472 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 882 | 0.030 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 532 | 0.030 |
Why?
| | Phenotype | 1 | 2019 | 3079 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1963 | 0.020 |
Why?
| | Glucose Transporter Type 5 | 1 | 2010 | 4 | 0.020 |
Why?
| | Glucose Transporter Type 2 | 1 | 2010 | 11 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2008 | 2727 | 0.020 |
Why?
| | Hyperplasia | 1 | 2010 | 168 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 48 | 0.020 |
Why?
| | Nephritis | 1 | 2009 | 30 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 1948 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 8 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 17 | 0.020 |
Why?
| | Disease Progression | 2 | 2007 | 2581 | 0.020 |
Why?
| | Starvation | 1 | 2008 | 26 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6885 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3172 | 0.020 |
Why?
| | Potassium, Dietary | 1 | 2007 | 11 | 0.020 |
Why?
| | Adenoviridae | 1 | 2008 | 195 | 0.020 |
Why?
| | Hypertrophy | 1 | 2008 | 125 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 107 | 0.020 |
Why?
| | Gout | 1 | 2008 | 57 | 0.020 |
Why?
| | Aldosterone | 1 | 2007 | 46 | 0.020 |
Why?
| | Actins | 1 | 2010 | 378 | 0.020 |
Why?
| | Hypothalamus | 1 | 2008 | 163 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2007 | 39 | 0.020 |
Why?
| | Urine | 1 | 2007 | 64 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2008 | 194 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 430 | 0.020 |
Why?
| | Magnesium | 1 | 2007 | 156 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 1811 | 0.020 |
Why?
| | Atrophy | 1 | 2007 | 158 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 523 | 0.020 |
Why?
| | Mice | 3 | 2009 | 15616 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 398 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2006 | 26 | 0.020 |
Why?
| | Fasting | 1 | 2008 | 279 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 381 | 0.020 |
Why?
| | Arterioles | 1 | 2006 | 45 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 188 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 28928 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 494 | 0.020 |
Why?
| | Sodium Chloride, Dietary | 1 | 2006 | 48 | 0.020 |
Why?
| | Angiotensin II | 1 | 2006 | 109 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 444 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2006 | 128 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1033 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2005 | 161 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2005 | 189 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 853 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4698 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2005 | 142 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2005 | 271 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9648 | 0.020 |
Why?
| | Antioxidants | 1 | 2008 | 580 | 0.020 |
Why?
| | NF-kappa B | 1 | 2008 | 672 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2008 | 463 | 0.020 |
Why?
| | Vasodilation | 1 | 2007 | 462 | 0.020 |
Why?
| | Body Composition | 1 | 2008 | 721 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1176 | 0.020 |
Why?
| | Reference Values | 1 | 2005 | 804 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2007 | 325 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 2814 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1137 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 1019 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2876 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1868 | 0.010 |
Why?
| | Aged | 1 | 2018 | 20688 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 987 | 0.010 |
Why?
| | RNA | 1 | 2005 | 859 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1553 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 1904 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2499 | 0.010 |
Why?
|
|
Roncal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|